- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cartesian Therapeutics Inc.(RNAC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RNAC
11/18/2026: RNAC (1-star) is currently NOT-A-BUY. Pass it for now.
Cartesian Therapeutics Inc. is a clinical-stage biotechnology stock pioneering RNA-engineered cell therapies for severe autoimmune conditions. The company's primary strength lies in its differentiated non-integrating mRNA platform and its advanced lead candidate, Descartes-08, which is moving through late-stage clinical trials. Its main growth opportunity rests on capturing market share in large immunological indications, offset by risks including early-stage operating losses, lack of commercial revenue, and heavy reliance on trial outcomes. The stock suits high-risk growth investors comfortable with clinical volatility, who should closely monitor upcoming Phase 3 data readouts and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Offers exposure to high-growth clinical-stage biotechnology innovation with potential pipeline catalysts. |
| Momentum investor | Strong fit while signal remains positive | Stock price action reacts sharply around clinical trial readouts and regulatory updates. |
| Value investor | Weak fit | Lacks current earnings, positive cash flow, or traditional valuation metrics. |
| Dividend investor | Weak fit | Does not pay dividends and retains all capital for clinical research. |
| Low-risk investor | Weak fit | Subject to high clinical development, regulatory, and stock price volatility risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks experience sharp price swings based on trial updates and market sentiment. |
| Valuation risk | High | Valuation is speculative and tied entirely to future drug approval probabilities rather than current cash generation. |
| Competition risk (biotech clinical development competition) | Medium / high | The company competes against well-funded rivals developing alternative treatments for autoimmune diseases. |
| Business quality | Medium | Features a specialized scientific platform, though unproven commercially at scale. |
| Dividend income | Low / none | No dividend is paid or expected in the near term. |
| Execution risk | High | Success depends heavily on successfully completing complex late-stage clinical trials and securing regulatory approval. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 189.12M USD | Price to earnings Ratio - | 1Y Target Price 33.67 |
Price to earnings Ratio - | 1Y Target Price 33.67 | ||
Volume (30-day avg) 140.7K shares | Beta 0.76 | 52 Weeks Range 5.60 - 11.00 | Updated Date 11/18/2026 |
52 Weeks Range 5.60 - 11.00 | Updated Date 11/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.78 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.0%
- Active BUY / eligible
- 67 / 108
- 30-Day BUY Count Change
- +22
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 43.6%
- Active BUY / eligible
- 17 / 39
- 30-Day BUY Count Change
- +10
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -71.47% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D and Collaboration | Grant funding, collaborative research agreements, and potential future commercial product sales from RNA cell therapies. | The company currently operates at a loss and generates negligible revenue while investing heavily in clinical trials. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 25.06 | Enterprise Value 124.04M | Price to Sales(TTM) 184.51 |
Enterprise Value 124.04M | Price to Sales(TTM) 184.51 | ||
Enterprise Value to Revenue 62.11 | Enterprise Value to EBITDA 1.77 | Shares Outstanding 30.50M | Shares Floating 11.73M |
Shares Outstanding 30.50M | Shares Floating 11.73M | ||
Percent Insiders 51.71 | Percent Institutions 28.79 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

